About 1 in 6 patients undergoing TAVR had ATTR cardiomyopathy on a bone scan.
Cardiac amyloidosis in 60 seconds, and how InVision Precision Cardiac Amyloid flags echos suggestive of amyloid.
AI Echo Decision support:
https://t.co/sjO7uS1E7J
1/n Excited to share AI ECHO INSIGHT, the first blinded, randomized trial of AI for the full echo report, presented today by Keane Lee at #ScientificSessions26 Late-Breaking Science.
EchoPrime and EchoNet-Measurements drafted the interpretations and measurements for cardiologist review. #echofirst
Precision medicines need a precision diagnosis. AL and ATTR amyloidosis need different treatments, and the workup starts with the echo.
Precision Cardiac Amyloid flags echocardiograms suggestive of cardiac amyloidosis.
Meet us at #AHA26 in Chicago.
https://t.co/v5XDyjQRJg
One thing I appreciate about @David_Ouyang is that he thinks about echo AI from the perspective of a practicing cardiologist and echocardiographer in the US today. Subtle decisions in how and why an AI model is built make a huge difference once it’s used at scale—which has to be the goal of any AI in healthcare.
"ATTR-CM is the zebra hiding among the horses." Medscape InDiscussion on AI in ATTR-CM, with Drs Kevin Alexander and Lily Stern.
Discussion of population detection approaches, include EchoNet-LVH, the model behind InVision Precision Cardiac Amyloid, FDA-cleared echo AI.
https://t.co/svkiUPqrF2
We're at #AHA26 in Chicago through Monday, Nov 9!
Meet the InVision team and see Precision Cardiac Amyloid: FDA-cleared echo AI that flags echocardiograms suggestive of cardiac amyloidosis, with no new scan.
https://t.co/v5XDyjQRJg
Heading to #AHA26 in Chicago, Nov 6–9?
Meet the InVision team. DM to set up a meeting.
Learn how Precision Cardiac Amyloid can assist in the detection of both ATTR-CM and AL-CM in your practice. PCA uses two standard echo views to achieve the highest specificity and PPV, and what to expect from its flags.
https://t.co/Pj23hNNVzk
Cardiac amyloidosis takes a median 39 months to diagnose. 42% of patients wait more than 4 years. Close the gap at the echo.
#WorldAmyloidosisDay#BeTheLink https://t.co/v5XDyjQRJg
Precision Cardiac Amyloid is FDA cleared for adults 65 years or older undergoing echocardiography.
When looking for the needle in the haystack, specificity matters. Specificity and PPV determine the performance of the detection algorithm in flagging patients for confirmatory testing.
Learn more at https://t.co/xN8fQhcT5j
InVision Precision Cardiac Amyloid reads the echo in-workflow and flags studies suggestive of cardiac amyloidosis.
99% specificity. FDA 510(k) cleared.
Find @AndrewSReeve on site at HFSA through Monday for more details or with questions.
#HeartFailure#HealthcareAI#ATTRCM #HFSA2026
A flag only helps if clinicians trust it enough to act. 99% specificity, high PPV, in-workflow on the echo being read.
Find @AndrewSReeve at #HFSA2026.
Arrived in PHX for #HFSA2026. Find the guy in the InVision vest!
Want to talk about finding cardiac amyloid earlier in HF patients? DM me and let's meet.
And check out this amazing site the @InVision_AI team put together on "The Amyloid Heart": https://t.co/5UsCw6du4A
Cardiac amyloidosis often shows up as HFpEF and gets managed as HFpEF before it's confirmed. Cardiac amyloidosis needs different treatment.
A high-specificity flag on the echo gets the right patients to confirmatory testing and therapy sooner.
At #HFSA2026 Oct 9-12. @InVision_AI
Not every clinician who sees cardiac amyloid runs our software. Now they don't have to.
A treating physician can send the echo to @imvariainc's AI Lab and get InVision PCA as a send-out test.
#ATTRCM#CardiacAmyloidosis
Live today: Medicare NTAP for InVision Precision Cardiac Amyloid. Up to $2,275 per eligible inpatient stay, on top of the MS-DRG.
FDA 510(k) cleared. 99% specificity.
#HFSA2026#ATTRCM